Skip to content
Precision for Medicine
Press Release

Precision Medicine Group joins McKesson's Oncology & Multispecialty segment. Read more in McKesson Business Highlights.

ON-DEMAND EXPERT PANEL

Could Australia be your fast track to global oncology development?

Discover how to maximize Australia’s early-phase advantages while preparing for FDA expectations and global development.

For biotech sponsors in China and across APAC, Australia has become a compelling location for Phase 1 oncology studies, combining regulatory efficiency with a mature clinical research ecosystem. When designed with global objectives in mind, these studies don’t just move faster – they can generate globally relevant data to advance broader regulatory and development goals.

In this webinar, you’ll hear from a former FDA oncology regulator, an experienced Phase 1 investigator and global development specialists as they explore how to make the most of Australia’s early-phase opportunities while laying the groundwork for future international trials.

Register to Watch Webinar

Sydney-Australia

 

The right decisions now can amplify what’s next.

Hear what our panel has to say about the advantages of getting started in Australia. Discover how early development decisions and evolving regulatory expectations can shape your international ambitions.

  • Your Australian head start
    Explore how Australia's efficient regulatory pathways can help sponsors accelerate study startup and gain momentum in early clinical development.
  • Building globally relevant evidence from Day 1
    Learn what makes Australian Phase 1 data particularly valuable in a broader development context and the considerations that can maximize its impact.
  • Anticipating the FDA
    Understand how early regulatory engagement and evolving FDA expectations, including Project Optimus, can influence your approach to dose optimization and evidence generation.
  • Sharpening your Phase 1 strategy
    Gain practical perspectives on study design and site selection, including why early investigator engagement can make a difference to patient recruitment.
  • Your launchpad for global development
    Discover how Australian trial data can contribute to a broader international strategy, and what sponsors should consider when planning for future regulatory submissions.

Hear from those who know what it takes.

What does the FDA look for in early oncology development? And what can sponsors learn from those already navigating the challenges of taking a program onto the global stage? Our panel brings together first-hand regulatory insight and practical experience of running early-phase oncology trials in Australia and beyond.  

  • Paz Vellanki

    Paz Vellanki, MD, PhD

    Vice President, Clinical Development, Oncology

    Precision for Medicine

    Former Associate Director in the FDA’s Division of Oncology, bringing first-hand insight into US regulatory expectations for oncology drug development.

    (SizeLimitingPyList: [linkedin])
  • Xin Chen

    Xin Chen, PhD

    Vice President, Head of Global Regulatory Affairs

    InnoCare Pharma

    Global regulatory affairs leader with more than 25 years of pharmaceutical industry experience.

    (SizeLimitingPyList: [linkedin])
  • Charlotte Lemech

    Charlotte Lemech, MBBS, BSc(med), FRACP, MD(res)

    Medical Director, Medical Oncologist

    Scientia Clinical Research Ltd

    Medical oncologist and principal investigator on more than 120 Phase 1 clinical trials, including studies involving antibody-drug conjugates and immunotherapies.

    (SizeLimitingPyList: [linkedin])
  • James Cheong

    James Cheong, BSC (Pharm), MBA

    Senior Vice President, APAC Clinical Solutions

    Precision for Medicine

    Senior clinical operations leader with over 30 years of experience across the pharmaceutical and CRO sectors.

    (SizeLimitingPyList: [linkedin])

Jing Ping Yeo

Your moderator

JingPing Yeo, PhD

Vice President, Clinical Solutions, Head of APAC, Precision for Medicine

Bringing almost 30 years of drug development experience in APAC to the discussion.

linkedin logo